11 β ‐Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
11 β ‐Hydroxysteroid dehydrogenase type 1 (11 β ‐HSD1) catalyses the intracellular conversion of inert cortisone to physiologically active cortisol, functioning to enhance local cortisol action beyond what would be predicted based on simple plasma exposures. Adipose tissue overexpression of 11 β ‐HSD1 in rodents to levels observed in human obesity can lead to a near complete metabolic syndrome phenotype, and inhibition of 11 β ‐HSD1 has been proposed to be of potential therapeutic benefit to patients with type 2 diabetes mellitus (T2DM). Recently published clinical results with the selective 11 β ‐HSD1 inhibitor, INCB13739, have, for the first time, provided evidence substantiating this hypothesis, and suggest that 11 β ‐HSD1 activity may be important in regulating glycaemia and cardiometabolic risk. In patients with T2DM failing metformin monotherapy, INCB13739 treatment achieves significant reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG), and when present improves hyperlipidaemia and hypertriglyceridaemia. Interestingly, these positive effects are observed primarily in subjects categorized as obese (body mass index, BMI > 30 kg/m 2 ) and not in subjects categorized as overweight (BMI ≤ 30 kg/m 2 ), underscoring the likely importance of adipose tissue 11 β ‐HSD1 activity to the cardiometabolic sequelae of obesity. This review summarizes the therapeutic rationale for 11 β ‐HSD1 inhibition, and describes in detail the metabolic and endocrinologic changes observed in patients with T2DM treated with INCB13739.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“These mice exhibit a phenotype closely resembling that of human metabolic syndrome including visceral obesity, insulin resistance, hyperlipidaemia, hyperphagia and hypertension [15,16].”
BackgroundDoes central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 1×
“Over 13 years have past since Paul Stewart and colleagues asked, ‘Does central obesity reflect Cushing’s disease of the omentum’? [34].”
BackgroundMorton, N. M., Paterson, J. M., Masuzaki, H., Holmes, M. C., Staels, B., Fievet, C., Walker, B. R., Flier, J. S., Mullins, J. J., & Seckl, J. R. (2004) · Diabetes · doi:10.2337/diabetes.53.4.931 · Cited by 512
Body fat distribution, insulin resistance, and metabolic diseases
Björntorp, P. (1997) · Nutrition · doi:10.1016/s0899-9007(97)00191-3 · Cited by 470
Masuzaki, H., Yamamoto, H., Kenyon, C. J., Elmquist, J. K., Morton, N. M., Paterson, J. M., Shinyama, H., Sharp, M. G. F., Fleming, S., Mullins, J. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17845 · Cited by 434 · cited 1×
“These mice exhibit a phenotype closely resembling that of human metabolic syndrome including visceral obesity, insulin resistance, hyperlipidaemia, hyperphagia and hypertension [15,16].”
BackgroundHormonal regulation of hepatic gluconeogenesis.
Kraus-Friedmann, N. (1984) · Physiological Reviews · doi:10.1152/physrev.1984.64.1.170 · Cited by 276
DIMITRIADIS, G., LEIGHTON, B., PARRY-BILLINGS, M., SASSON, S., YOUNG, M., KRAUSE, U., BEVAN, S., PIVA, T., WEGENER, G., & NEWSHOLME, E. A. (1997) · Biochemical Journal · doi:10.1042/bj3210707 · Cited by 266
Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans
Djurhuus, C. B., Gravholt, C. H., Nielsen, S., Mengel, A., Christiansen, J. S., Schmitz, O. E., & Møller, N. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00544.2001 · Cited by 219
Kannisto, K., Pietiläinen, K. H., Ehrenborg, E., Rissanen, A., Kaprio, J., Hamsten, A., & Yki-Järvinen, H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0153 · Cited by 205
Cited by
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis
Holst, J. J., Wewer Albrechtsen, N. J., Pedersen, J., & Knop, F. K. (2017) · Diabetes · doi:10.2337/db16-0994 · Cited by 187
The multifaceted mineralocorticoid receptor
Gomez‐Sanchez, E., & Gomez‐Sanchez, C. E. (2014) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2014.tb00569.x · Cited by 55
Li, X., Hu, S., Zhu, Q., Yao, G., Yao, J., Li, J., Wang, Y., Ding, Y., Qi, J., Xu, R., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154749 · Cited by 26
Metadata
- Authors
- Hollis, G., & Huber, R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2010-11-28
- Volume
- 13
- Issue
- 1
- Pages
- 1-6
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2022227132
- Cited by
- 72
- References
- 9
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 11 β ‐Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01305.x
- The paper
- Hollis, G., & Huber, R. (2011). 11 β ‐Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01305.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.